- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

H.R. 2214
U.S. House•In House Committee
Summary
H.R. 2214, the DRUG Act, was introduced in the House on Mar 18, 2025 by Rep. Mariannette Miller-Meeks (R) with 6 co-sponsors. It was referred to Energy And Commerce, and last saw action on Mar 18, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Record
Text
H.R. 2214 has 6 co-sponsors.
hb2214/introduced-in-house.txt119 HR 2214 IH: Delinking Revenue from Unfair Gouging ActU.S. House of Representatives2025-03-18text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.I 119th CONGRESS 1st Session H. R. 2214 IN THE HOUSE OF REPRESENTATIVES March 18, 2025 Mrs. Miller-Meeks (for herself, Ms. Barragán , Ms. Malliotakis , Mr. Schneider , Mr. Allen , and Mr. Norcross ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committees on Ways and Means , and Education and Workforce , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILLTo improve services provided by pharmacy benefit managers.1.Short titleThis Act may be cited as the Delinking Revenue from Unfair Gouging Act or the DRUG Act .2.Improving pharmacy benefit manager services(a)Public Health Service ActPart D of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg–111 et seq. ) is amended by adding at the end the following:2799A–11.Improving pharmacy benefit manager services(a)In generalBeginning on January 1, 2027, except as provided in subsection (b), a pharmacy benefit manager shall derive no remuneration from any entity for services, benefit administration, or any other activities related to prescription drug benefits under a group health plan or group or individual health insurance coverage.(b)Exception for bona fide service fees(1)In generalA pharmacy benefit manager may charge an entity a bona fide service fee for the provision of services to such entity only if such fee is set forth in an agreement between the pharmacy benefit manager and such entity and the amount of any bona fide service fee—(A)is a flat dollar amount; and(B)is not directly or indirectly based on, or contingent upon—(i)a drug price (such as wholesale acquisition cost) or drug benchmark price (such as average wholesale price);(ii)the amount of discounts, rebates, fees, or other direct or indirect remuneration with respect to prescription drugs prescribed to the participants, beneficiaries, or enrollees in the group health plan or health insurance coverage involved; or(iii)any other amounts specified by the Secretary, the Secretary of Labor, and the Secretary of the Treasury;(2)DefinitionsIn this section—(A)the term bona fide service fee means a fee that is equal to the fair market value of a bona fide, itemized service that is actually performed on behalf of an entity, that the entity would otherwise perform (or contract for) in the absence of the service arrangement, and that is not passed on in whole or in part to a client or customer, whether or not the entity takes title to the drug; and(B)the term pharmacy benefit manager means any person, business, or other entity, such as a third-party administrator, regardless of whether it identifies itself as a pharmacy benefit manager, that, either directly or through an intermediary (including an affiliate, subsidiary, or agent) or an arrangement with a third-party—(i)acts a price negotiator for prescription drugs on behalf of a group health plan or health insurance issuer offering group or individual health insurance coverage; or(ii)manages or administers the prescription drug benefits provided by a group health plan or health insurance issuer offering group or individual health insurance coverage, including creating formularies, the processing and payment of claims for prescription drugs, arranging alternative access to or funding for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies (including retail and mail pharmacies), controlling the cost of covered prescription drugs, or the provision of related services.(c)Enforcement(1)In generalThe Secretary, in consultation with the Secretary of Labor and the Secretary of the Treasury, shall enforce this section.(2)DisgorgementThe pharmacy benefit manager shall disgorge to a group health plan or health insurance issuer offering group or individual health insurance coverage any payment, remuneration, or other amount received by the pharmacy benefit manager or an affiliate of such pharmacy benefit manager from such plan or issuer in violation of subsection (a) or, pursuant to subsection (b), the agreement entered into with such plan or issuer for bona fide service fees.(3)PenaltiesA pharmacy benefit manager that violates subsection (a) or (b) shall be subject to a civil monetary penalty in the amount of $10,000 for each day during which such violation continues.(4)ProcedureNotwithstanding section 2723, the provisions of section 1128A of the Social Security Act, other than subsection (a) and (b) and the first sentence of subsection (c)(1) of such section, shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1128A of the Social Security Act.(d)RegulationsNotwithstanding any other provision of law, the Secretary, in consultation with the Secretary of Labor and the Secretary of the Treasury, shall implement this section through interim final regulations.(e)Rules of constructionNothing in this section shall be construed—(1)as prohibiting payments related to reimbursement for ingredient costs to entities that acquire prescription drugs or pharmacy dispensing fees; and(2)to prohibit rebates, discounts, or other price concessions from being fully passed through to a group health plan or health insurance issuer offering group or individual health insurance coverage to lower net costs for prescription drugs..(b)ERISA(1)In generalSubpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1185 et seq. ) is amended by inserting after section 725 the following:726.Improving pharmacy benefit manager services(a)GeneralBeginning on January 1, 2027, except as provided in subsection (b), a pharmacy benefit manager shall derive no remuneration from any entity for services, benefit administration, or any other activities related to prescription drug benefits under a group health plan or group health insurance coverage.(b)Exception for bona fide service fees(1)In generalA pharmacy benefit manager may charge an entity a bona fide service fee for the provision of services to an entity only if such fee is set forth in an agreement between the pharmacy benefit manager and such entity and the amount of any bona fide service fee—(A)is a flat dollar amount; and(B)is not directly or indirectly based on, or contingent upon—(i)a drug price (such as wholesale acquisition cost) or drug benchmark price (such as average wholesale price);(ii)the amount of discounts, rebates, fees, or other direct or indirect remuneration with respect to prescription drugs prescribed to the participants, beneficiaries, or enrollees in the group health plan or health insurance coverage involved; or(iii)any other amounts specified by the Secretary, the Secretary of Health and Human Services, and the Secretary of the Treasury.(2)DefinitionsIn this section—(A)the term bona fide service fee means a fee that is equal to the fair market value of a bona fide, itemized service that is actually performed on behalf of an entity, that the entity would otherwise perform (or contract for) in the absence of the service arrangement, and that is not passed on in whole or in part to a client or customer, whether or not the entity takes title to the drug; and(B)the term pharmacy benefit manager means any person, business, or other entity, such as a third-party administrator, regardless of whether it identifies itself as a pharmacy benefit manager, that, either directly or through an intermediary (including an affiliate, subsidiary, or agent) or an arrangement with a third-party—(i)acts a price negotiator for prescription drugs on behalf of a group health plan or health insurance issuer offering group health insurance coverage; or(ii)manages or administers the prescription drug benefits provided by a group health plan or health insurance issuer offering group health insurance coverage, including creating formularies, the processing and payment of claims for prescription drugs, arranging alternative access to or funding for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies (including retail and mail pharmacies), controlling the cost of covered prescription drugs, or the provision of related services.(c)EnforcementThe Secretary shall enforce this section as provided for in section 502(c)(13).(d)RegulationsNotwithstanding any other provision of law, the Secretary, in consultation with the Secretary of Health and Human Services and the Secretary of the Treasury, shall implement this section through interim final regulations.(e)Rules of constructionNothing in this section shall be construed—(1)as prohibiting payments related to reimbursement for ingredient costs to entities that acquire prescription drugs or pharmacy dispensing fees; and(2)to prohibit rebates, discounts, or other price concessions from being fully passed through to a group health plan or health insurance issuer offering group health insurance coverage to lower net costs for prescription drugs..(2)EnforcementSection 502 of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1132 ) is amended—(A)in subsection (a)(6), by striking or (9) and inserting (9), or (13) ; and(B)in subsection (c), by adding at the end the following:(13)Secretarial enforcement authority relating to pharmacy benefit manager services(A)DisgorgementWith respect to a violation of section 726 by a pharmacy benefit manager, such pharmacy benefit manager shall disgorge to a group health plan or health insurance issuer offering group health insurance coverage any payment, remuneration, or other amount received by the pharmacy benefit manager or an affiliate of such pharmacy benefit manager from such plan or issuer in violation of subsection (a) of such section or, pursuant to subsection (b) of such section, the agreement entered into with such plan or issuer for bona fide service fees.(B)PenaltiesA pharmacy benefit manager that violates subsection (a) or (b) of section 726 shall be subject to a civil monetary penalty in the amount of $10,000 for each day during which such violation continues.(C)ProcedureExcept as provided in this paragraph, the provisions of this section shall apply to civil monetary penalties under this paragraph in the same manner as such provisions apply to other civil penalties under this section.(D)Rule of constructionNothing in this paragraph shall effect the authority of the Secretary under subsection (a)(5)..(3)Clerical amendmentThe table of contents in section 1 of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1001 et seq. ) is amended by inserting after the item relating to section 725 the following new item:Sec. 726. Improving pharmacy benefit manager services.(c)Internal Revenue Code of 1986(1)In generalSubchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following:9826.Improving pharmacy benefit manager services(a)In generalBeginning on January 1, 2027, except as provided in subsection (b), a pharmacy benefit manager shall derive no remuneration from any entity for services, benefit administration, or any other activities related to prescription drug benefits under a group health plan.(b)Exception for bona fide service fees(1)In generalA pharmacy benefit manager may charge an entity a bona fide service fee for the provision of services to such entity only if such fee is set forth in an agreement between the pharmacy benefit manager and such entity and the amount of any bona fide service fee—(A)is a flat dollar amount; and(B)is not directly or indirectly based on, or contingent upon—(i)a drug price (such as wholesale acquisition cost) or drug benchmark price (such as average wholesale price);(ii)the amount of discounts, rebates, fees, or other direct or indirect remuneration with respect to prescription drugs prescribed to the participants, beneficiaries, or enrollees in the group health plan involved; or(iii)any other amounts specified by the Secretary, the Secretary of Health and Human Services, and the Secretary of the Labor.(2)DefinitionsIn this section—(A)the term bona fide service fee means a fee that is equal to the fair market value of a bona fide, itemized service that is actually performed on behalf of an entity, that the entity would otherwise perform (or contract for) in the absence of the service arrangement, and that is not passed on in whole or in part to a client or customer, whether or not the entity takes title to the drug; and(B)the term pharmacy benefit manager means any person, business, or other entity such as a third-party administrator, regardless of whether it identifies itself as a pharmacy benefit manager, that, either directly or through an intermediary (including an affiliate, subsidiary, or agent) or an arrangement with a third-party—(i)acts as a price negotiator for prescription drugs on behalf of a group health plan; or(ii)manages or administers the prescription drug benefits provided by a group health plan, including creating formularies, the processing and payment of claims for prescription drugs, arranging alternative access to or funding for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies, controlling the cost of covered prescription drugs, or the provision of related services.(c)Enforcement(1)In generalThe Secretary, in consultation with the Secretary of Health and Human Services and the Secretary of Labor, shall enforce this section.(2)DisgorgementThe pharmacy benefit manager shall disgorge to a group health plan any payment, remuneration, or other amount received by the pharmacy benefit manager or an affiliate of such pharmacy benefit manager from such plan or issuer in violation of subsection (a) or, pursuant to subsection (b), the agreement entered into with such plan for bona fide service fees.(3)PenaltiesA pharmacy benefit manager that violates subsection (a) or (b) shall be subject to a civil monetary penalty in the amount of $10,000 for each day during which such violation continues.(4)ProcedureThe provisions of section 1128A of the Social Security Act, other than subsection (a) and (b) and the first sentence of subsection (c)(1) of such section, shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1128A of the Social Security Act.(d)RegulationsNotwithstanding any other provision of law, the Secretary, in consultation with the Secretary of Health and Human Services and the Secretary of Labor, shall implement this section through interim final regulations..(2)Clerical amendmentThe table of sections for subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:Sec. 9826. Improving pharmacy benefit manager services..
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-03-18
- Passed House
- Passed Senate
- Conference
- To President
- Became Law
To improve services provided by pharmacy benefit managers.
Sponsors
Rep. Mariannette Miller-Meeks (R) sponsors H.R. 2214, and 6 members have co-sponsored it, 5 of them from the day it was introduced.

Rep. · R–IA-1 · Sponsor
Introduced Mar 18, 2025

Rep. · R–GA-12 · Co-sponsor
Joined Mar 18, 2025 · Original

Rep. · D–CA-44 · Co-sponsor
Joined Mar 18, 2025 · Original

Rep. · R–NY-11 · Co-sponsor
Joined Mar 18, 2025 · Original

Rep. · D–NJ-1 · Co-sponsor
Joined Mar 18, 2025 · Original

Rep. · D–IL-10 · Co-sponsor
Joined Mar 18, 2025 · Original

Rep. · D–MI-13 · Co-sponsor
Joined Nov 4, 2025
Committees
H.R. 2214 went before 3 committees: Education and Workforce, Ways and Means and Energy and Commerce.
Actions
H.R. 2214 has taken 2 actions since Mar 18, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
Mar 18, 2025 | House | Introduced in House | ||
Mar 18, 2025 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee |
Votes
H.R. 2214 has not gone to a roll call.
Titles
H.R. 2214 goes by 4 titles, 2 of them short titles.
- DRUG Act — Display Title
- DRUG Act — Short Title(s) as Introduced
- Delinking Revenue from Unfair Gouging Act — Short Title(s) as Introduced
- To improve services provided by pharmacy benefit managers. — Official Title as Introduced
Lobbying
22 clients hired 28 firms and 182 registered lobbyists who named H.R. 2214 in 142 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Health Issues, Medicare/Medicaid, Pharmacy, Trade (domestic/foreign), Budget/Appropriations, Copyright/Patent/Trademark, Taxation/Internal Revenue Code, Defense.
Clients
Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 22.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | trade association representing Americas pharmacy benefits managers | District of Columbia | 3 | 17 | $560K |
| PRIME THERAPEUTICS | Pharmacy Benefit Management | Minnesota | 3 | 12 | $200K |
| PFIZER INC. | Biopharmaceutical company. | District of Columbia | 2 | 11 | $260K |
| NOVARTIS | — | District of Columbia | 1 | 8 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | Trade association for the Pharmaceutical Research and Manufacturer's of America | District of Columbia | 1 | 7 | $280K |
| ELEVANCE HEALTH, INC. | — | District of Columbia | 1 | 7 | — |
| GSK (FKA GLAXOSMITHKLINE INC.) | — | District of Columbia | 1 | 7 | — |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | — | District of Columbia | 1 | 7 | — |
| SOUTHEAST GEORGIA HOSPITAL SYSTEM | Hospital System, three hospitals and a nursing home | Georgia | 1 | 6 | $120K |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | — | District of Columbia | 1 | 6 | — |
| CVS HEALTH (AND SUBSIDIARIES) | Health Care | District of Columbia | 1 | 6 | — |
| EMD SERONO INC | — | District of Columbia | 1 | 6 | — |
| JOHNSON & JOHNSON SERVICES INC | — | New Jersey | 1 | 6 | — |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | — | Virginia | 1 | 6 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | — | District of Columbia | 1 | 6 | — |
| YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOW | Government affairs and strategic advisory services firm | District of Columbia | 2 | 5 | $30K |
| AMGEN INC | — | District of Columbia | 1 | 5 | — |
| GOVERNMENT COUNSEL, LLC (OBO) PRIME THERAPEUTICS | ​Public Policy and Government Advisory Firm | Florida | 1 | 4 | $40K |
| AMERICAN PHARMACIES, INC. | Independent pharmacy services group | Texas | 1 | 3 | $180K |
| TAKEDA PHARMACEUTICALS AMERICA INC | — | District of Columbia | 1 | 3 | — |
Firms
Registrants who filed on the bill, by filings.
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 182.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| COURTNEY LEE-ASHLEY | 1 | 1 | 8 |
| COURTNEY PIRON | 1 | 1 | 8 |
| JOSEPH MCGOWAN | 1 | 1 | 8 |
| SARAH DURR | 1 | 1 | 8 |
| TAYLOR BOOTH | 1 | 1 | 8 |
| THOMAS SUTER | 1 | 1 | 8 |
| ADAM GOLDBERG | 1 | 1 | 7 |
| ANTHONY BUSH | 1 | 1 | 7 |
| CHRISTOPHER HARTMANN | 1 | 1 | 7 |
| COURTNEY LAWRENCE | 1 | 1 | 7 |
| ELIZABETH HALL | 1 | 1 | 7 |
| EMILY THREADGILL | 1 | 1 | 7 |
| HARMEET DHILLON | 1 | 1 | 7 |
| JONATHAN BONET-RIVERA | 1 | 1 | 7 |
| JONATHAN HEAFITZ | 1 | 1 | 7 |
| JULIEN RELFE | 1 | 1 | 7 |
| KATHRYN GALLAGHER | 1 | 1 | 7 |
| LADAN AHMADI | 1 | 1 | 7 |
| LEO FARBER | 1 | 1 | 7 |
| LIAM MACDONALD | 1 | 1 | 7 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 first_quarter | $12.9M | 1st Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 first_quarter | $12.2M | 1st Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 third_quarter | $9M | 3rd Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 fourth_quarter | $8.4M | 4th Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 second_quarter | $7.6M | 2nd Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 second_quarter | $7.4M | 2nd Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2026 first_quarter | $5.3M | 1st Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2025 first_quarter | $4.8M | 1st Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2025 third_quarter | $4.2M | 3rd Quarter - Report |
| NOVARTIS | NOVARTIS | 2025 first_quarter | $4.2M | 1st Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2025 fourth_quarter | $4.1M | 4th Quarter - Report |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2025 first_quarter | $4.1M | 1st Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2025 second_quarter | $4.1M | 2nd Quarter - Report |
| NOVARTIS | NOVARTIS | 2026 first_quarter | $3.9M | 1st Quarter - Report |
| PFIZER INC. | PFIZER INC. | 2025 second_quarter | $3.7M | 2nd Quarter - Amendme… |
| PFIZER INC. | PFIZER INC. | 2025 second_quarter | $3.7M | 2nd Quarter - Amendme… |
| AMGEN INC | AMGEN, INC. | 2025 first_quarter | $3.6M | 1st Quarter - Report |
| CVS HEALTH (AND SUBSIDIARIES) | CVS HEALTH (AND SUBSIDIARIES) | 2026 second_quarter | $3.6M | 2nd Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2025 fourth_quarter | $3.6M | 4th Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2025 third_quarter | $3.6M | 3rd Quarter - Report |
Classification
The Congressional Research Service files H.R. 2214 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; H.R. 2214’s is Health.
hr2214/policy-areas.txtSource: congress.gov · legiscan.com